Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
It is the first monoclonal antibody drug for use in any animal species
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Biogen paid Ionis a US $ 60 million one-time upfront payment
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
It is a novel oral NLRP3 inflammasome inhibitor
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities
The week-long campaign received a record 17.691 pledges
Subscribe To Our Newsletter & Stay Updated
